Vor Biopharma
Vor Biopharma Inc is an American clinical-stage biopharmaceutical enterprise headquartered in Cambridge, Massachusetts. The company specializes in the development of engineered hematopoietic stem cell (HSC) therapies designed to improve the effectiveness and safety of cancer treatments (such as CAR-T therapies), utilizing proprietary cell-engineering technology to create treatment-resistant blood cells. Principal revenue is currently earned through research collaborations, grant funding, and capital financing arrangements as clinical pipelines advance. Vor Biopharma is publicly listed on the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in Vor Biopharma.
- Legal name
- Vor Biopharma Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
- Exposure themes
- Autoimmune diseases, Treatment, Women's Health
Funds holding Vor Biopharma
- DNB Fund Women's Health — DNB · 1.7 % (full portfolio disclosed, August 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.25 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.08 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)